Following single oral doses in cynomolgus monkeys, saxagliptin inhibited ex vivo plasma DPP activity at 24 hours. The two assay formats gave statistically similar saxagliptin results, while sitagliptin results differed by assay. The biomarker therefore requires assay-specific interpretation; it is not a direct measurement of glucose lowering. [1]
In lean male C57BL/6N mice, a single oral saxagliptin dose produced dose-dependent plasma DPP4 inhibition measured 70 minutes later. The saxagliptin series in Figure 3 spans 0.01–1 mg/kg. Results were normalized to the vehicle group and were uncorrected for plasma dilution; they describe acute target engagement under this assay. [3]
Monkey plasma DPP inhibition depends on assay and inhibitor
Animal study · Male and female cynomolgus monkeys; six per dose group; weekly crossover dosing [1]
Saxagliptin produced persistent ex vivo plasma DPP inhibition at 24 h. Assay concordance for saxagliptin contrasted with substrate-dependent detection of sitagliptin inhibition.
Conditions shared by the study groups
- Route
- Oral gavage
- Frequency
- Single dose per weekly crossover period
- Treatment course
- 24 h postdose endpoint
- Vehicle
- Water, final pH 5.0
- Saxagliptin crossover dose series
- Model: Male and female cynomolgus monkeys; six per dose group; weekly crossover dosing
- Reported limits: Exact crossover sequence and total number of unique animals are not specified in the read Methods.
Methods and source locations
Compound reported in the paper: Saxagliptin (BMS-477118); Compound label in the paper: Saxagliptin
Animal pharmacodynamic biomarker evidence; no glucose efficacy or clinical equivalence claim.
Figure 4 image/caption and Results: Measurement of plasma DPP activity in ex vivo assays; Methods: monkey crossover, both plasma assays and statistical analysis
Plasma DPP activity at 24 h: Ala-Pro-AFC fluorescence at room temperature versus Gly-Pro-pNA absorbance at 30°C on identical plasma samples; Dunnett comparison to vehicle, Tukey HSD pairwise comparisons. — Figure 4 image/caption and Results: Measurement of plasma DPP activity in ex vivo assays; Methods: monkey crossover, both plasma assays and statistical analysis
Saxagliptin crossover dose series · Figure 4 image/caption and Results: Measurement of plasma DPP activity in ex vivo assays; Methods: monkey crossover, both plasma assays and statistical analysis
Acute oral saxagliptin inhibits mouse plasma DPP4
Animal study · Male C57BL/6N mice, 7–12 weeks, 19–26 g; n = 20–28/group in the ex vivo cohort [3]
Saxagliptin dose-dependently inhibited plasma DPP4 activity after an oral dose in lean mice. This is a separate target-engagement cohort from the paper’s glucose-tolerance cohort.
Conditions shared by the study groups
- Route
- Oral gavage
- Frequency
- Single administration
- Treatment course
- 70 min after inhibitor dose; 10 min after oral dextrose challenge
- Vehicle
- 0.25% methylcellulose, 5 mL/kg
- Saxagliptin acute target-engagement series
- Model: Male C57BL/6N mice, 7–12 weeks, 19–26 g; n = 20–28/group in the ex vivo cohort
- Reported limits: Per-dose n within the stated 20–28/group range is not provided; no predose sample was collected.
Methods and source locations
Compound reported in the paper: Saxagliptin (BMS-477118); Compound label in the paper: Saxagliptin
Lean-mouse target engagement; not chronic diabetes efficacy, clinical efficacy or a quantitative cross-paper potency comparison.
Figure 3 image/caption; Methods 2.1 Reagents/Animals and 2.3 Measurement of murine plasma DPP-4 activity ex vivo; Results 3.3
Plasma DPP4 inhibition at 70 min: Continuous fluorescence Gly-Pro-AMC assay; 50% plasma, 50 μmol/L substrate; activity normalized to arithmetic mean of vehicle group rather than within-animal predose activity. — Figure 3 image/caption; Methods 2.1 Reagents/Animals and 2.3 Measurement of murine plasma DPP-4 activity ex vivo; Results 3.3
Saxagliptin acute target-engagement series · Figure 3 image/caption; Methods 2.1 Reagents/Animals and 2.3 Measurement of murine plasma DPP-4 activity ex vivo; Results 3.3